Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan

Editorial Material Dermatology

Real-world effectiveness and safety of baricitinib in Japanese patients with atopic dermatitis: A single-center retrospective study

Akihiko Uchiyama et al.

JOURNAL OF DERMATOLOGY (2022)

Review Dermatology

Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis

Huiying Wan et al.

Summary: This study conducted a network meta-analysis to compare the efficacy and safety of three common oral JAK inhibitors, abrocitinib, baricitinib, and upadacitinib, for moderate-to-severe atopic dermatitis (AD). The results showed that all three treatments were effective, but upadacitinib 30 mg may be the optimal option in short-term studies, although it had a higher risk of treatment-emergent adverse events (TEAEs).

DERMATOLOGIC THERAPY (2022)

Add to Collection

Article Dermatology

The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan

Teppei Hagino et al.

Summary: This study evaluated the efficacy and safety of upadacitinib, a janus kinase 1 inhibitor, in real-world practice for the treatment of atopic dermatitis. The results showed that upadacitinib, in combination with topical corticosteroids, significantly improved clinical outcomes in patients with moderate-to-severe atopic dermatitis and was well tolerated. The study also found that female patients had better short-term response and that the initial total eosinophil count could predict treatment efficacy. These findings have important implications for guiding the treatment of atopic dermatitis.

JOURNAL OF DERMATOLOGY (2022)

Add to Collection

Review Allergy

Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2021

Hidehisa Saeki et al.

Summary: This is an abridged edition of the 2021 Clinical Practice Guidelines for the Management of Atopic Dermatitis, providing strategies for the treatment of AD and introducing new drugs.

ALLERGOLOGY INTERNATIONAL (2022)

Add to Collection

Article Dermatology

Improvement of head and neck symptoms in patients with atopic dermatitis treated with baricitinib based on five Phase III clinical trials

Andreas Wollenberg et al.

Summary: Baricitinib 2-mg and 4-mg treatment has shown rapid and substantial reduction in AD head and neck severity, including erythema, in patients with moderate-to-severe atopic dermatitis.

EUROPEAN JOURNAL OF DERMATOLOGY (2022)

Add to Collection

Review Dermatology

Facial and neck erythema associated with dupilumab treatment: A systematic review

Christine E. Jo et al.

Summary: This study summarized 101 cases of dupilumab-associated facial or neck erythema, with some patients showing symptoms from baseline atopic dermatitis while others possibly having different etiologies. Treatment strategies included topical corticosteroids and other medications, with patients showing varying degrees of improvement or worsening in symptoms.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Add to Collection

Review Dermatology

Facial and neck erythema associated with dupilumab treatment: A review

Christine E. Jo et al.

Summary: In this study, a total of 101 patients with dupilumab-associated facial or neck erythema were analyzed. Different etiologies, including rosacea and allergic contact dermatitis, were suggested. Prompt identification and treatment may help alleviate distress and prevent discontinuation of dupilumab.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems